| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2022 | 28% | SVB Leerink | $30 → $8 | Downgrades | Outperform → Market Perform |
| 05/25/2022 | — | Credit Suisse | Upgrades | Underperform → Neutral | |
| 04/27/2022 | 364% | SVB Leerink | $42 → $29 | Maintains | Outperform |
| 01/14/2022 | 572% | SVB Leerink | $35 → $42 | Maintains | Outperform |
| 08/27/2021 | 460% | SVB Leerink | $36 → $35 | Maintains | Outperform |
| 07/13/2021 | 700% | Cowen & Co. | → $50 | Initiates Coverage On | → Outperform |
| 06/21/2021 | 300% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
Molecular Partners Questions & Answers
The latest price target for Molecular Partners (NASDAQ: MOLN) was reported by SVB Leerink on August 29, 2022. The analyst firm set a price target for $8.00 expecting MOLN to rise to within 12 months (a possible 28.00% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Molecular Partners (NASDAQ: MOLN) was provided by SVB Leerink, and Molecular Partners downgraded their market perform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Molecular Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Molecular Partners was filed on August 29, 2022 so you should expect the next rating to be made available sometime around August 29, 2023.
While ratings are subjective and will change, the latest Molecular Partners (MOLN) rating was a downgraded with a price target of $30.00 to $8.00. The current price Molecular Partners (MOLN) is trading at is $6.25, which is out of the analyst's predicted range.